Journal of Substance Abuse Treatment
Volume 39, Issue 2 , Pages 157-166 , September 2010

Antidepressant treatment does not improve buprenorphine retention among opioid-dependent persons

  • Michael D. Stein, M.D

      Affiliations

    • Butler Hospital, Providence, RI 02906, USA
    • Warren Alpert School of Medicine at Brown University, Providence, RI 02912, USA
    • Corresponding Author InformationCorresponding author. Brown University, Butler Hospital, General Medicine Research, 345 Blackstone Blvd., Providence, RI 02906, USA. Tel.: +1 401 455 6646; fax: +1 401 455 6618.
    • ,
  • Debra S. Herman, Ph.D

      Affiliations

    • Butler Hospital, Providence, RI 02906, USA
    • Warren Alpert School of Medicine at Brown University, Providence, RI 02912, USA
    • ,
  • Malyna Kettavong, B.A

      Affiliations

    • Butler Hospital, Providence, RI 02906, USA
    • ,
  • Patricia A. Cioe, R.N.P

      Affiliations

    • Rhode Island Hospital, Providence, RI 02903, USA
    • ,
  • Peter D. Friedmann, M.D., M.P.H

      Affiliations

    • Rhode Island Hospital, Providence, RI 02903, USA
    • ,
  • Tahir Tellioglu, M.D

      Affiliations

    • Rhode Island Hospital, Providence, RI 02903, USA
    • ,
  • Bradley J. Anderson, Ph.D

      Affiliations

    • Butler Hospital, Providence, RI 02906, USA

Received 22 December 2009 ,Revised 14 April 2010 ,Accepted 3 May 2010.

References 

  1. Beck A, Steer R, Ball R, Ranieri W. Comparison of Beck Depression Inventories-IA and -II in psychiatric outpatients. Journal of Personality Assessment. 1996;67:588–597
  2. Brienza R, Stein M, Chen M, Gogineni A, Sobota M, Maksad J, et al. Depression among needle exchange program and methadone maintenance clients. Journal of Substance Abuse Treatment. 2000;18:331–337
  3. Brooner R, King V, Kidorf M, Schmidt C, Bigelow G. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Archives of General Psychiatry. 1997;54:71–80
  4. Bryant K, Rounsaville B, Spitzer R, Williams J. Reliability of dual diagnosis: Substance dependence and psychiatric disorders. Journal of Nervous and Mental Disease. 1992;180:251–257
  5. Croughan J, Miller J, Wagelin D, Whitman B. Psychiatric illness in male and female narcotic addicts. Journal of Clinical Psychiatry. 1982;43:225–228
  6. Darke S, Mills K, Teesson M, Ross J, Williamson A, Havard A. Patterns of major depression and drug-related problems amongst heroin users across 36 months. Psychiatry Research. 2009;166:7–14
  7. Dean A, Bell J, Christie M, Mattick R. Depressive symptoms during buprenorphine vs. methadone maintenance: Findings from a randomised, controlled trial in opioid dependence. European Psychiatry. 2004;19:510–513
  8. Farre M, Mas A, Torrens M, Moreno V, Cami J. Retention rate and illicit opioid use during methadone maintenance interventions: A meta-analysis. Drug and Alcohol Dependence. 2002;65:283–290
  9. Fiellin D, Barthwell A, Treatment Center for Substance Abuse Treatment . Guideline development for office-based pharmacotherapies for opioid dependence. Journal of Addictive Diseases. 2003;22:109–120
  10. Fiellin D, Pantalon M, Chawarski M, O'Connor P, Schottenfeld R. Counseling plus buprenorphine–naloxone maintenance therapy for opioid dependence. New England Journal of Medicine. 2006;355:365–374
  11. Finch J, Kamien J, Amass L. Two-year experience with buprenorphine–naloxone (suboxone) for maintenance treatment of opioid dependence within a private practice setting. Journal of Addiction Medicine. 2007;1:104–110
  12. First M, Spitzer R, Williams J, Gibbon M. Structured clinical interview for DSM-IV—patient version. New York, NY: NY State Psychiatric Institute; 1995;
  13. Fudala P, Bridge T, Herbert S, Williford W, Chiang C, Jones K, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. New England Journal of Medicine. 2003;349:949–958
  14. Gerra G, Borella F, Zaimovic A, Moi G, Bussandri M, Bubici C, et al. Buprenorphine versus methadone for opioid dependence: Predictor variables for treatment outcome. Drug and Alcohol Dependence. 2004;75:37–45
  15. Hasin D, Trautman K, Endicott J. Psychiatric research interview for substance and mental disorders: Phenomenologically based diagnosis in patients who abuse alcohol or drugs. Pharmacological Bulletin. 1998;34:3–8
  16. Hausman J. Specification tests in econometrics. Econometrica. 1978;46:1251–1271
  17. Havard A, Teesson M, Darke S, Ross J. Depression among heroin users: 12-Month outcomes from the Australian Treatment Outcome Study (ATOS). Journal of Substance Abuse Treatment. 2006;30:355–362
  18. Hess M. The Beck Depression Inventory in patients undergoing opiate agonist maintenance treatment. British Journal of Clinical Psychology. 2006;45:417–425
  19. Hulse G, English D, Milne E, Holman C. The quantification of mortality resulting from the regular use of illicit opiates. Addiction. 1999;94:221–229
  20. Johnson R, Chutuape M, Strain E, Walsh S, Stitzer M, Bigelow G. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. New England Journal of Medicine. 2000;343:1290–1297
  21. Kadden R, Kranzler H, Rounsaville B. Validity of the distinction between “substance-induced” and “independent” depression and anxiety disorders. American Journal on Addictions. 1995;4:107–117
  22. Kessler R, Zhao S, Katz S, Kouzis A, Frank R, Edlund M, et al. Past-year use of outpatient services for psychiatric problems in the National Comorbidity Survey. American Journal of Psychiatry. 1999;156:115–123
  23. Khantzian E, Treece C. DSM-III psychiatric diagnosis of narcotic addicts: Recent findings. Archives of General Psychiatry. 1985;42:1067–1071
  24. Kosten T, Morgan C, Kosten T. Depressive symptoms during buprenorphine treatment of opioid abusers. Journal of Substance Abuse Treatment. 1990;7:51–54
  25. Kosten T, Rounsaville B. Suicidality among opioid addicts: 2.5 year follow-up. American Journal of Drug and Alcohol Abuse. 1988;14:357–369
  26. Kranzler H, Kadden R, Babor T, Tennen H, Rounsaville B. Validity of the SCID in substance abuse patients. Addiction. 1996;91:859–868
  27. Kranzler H, Kadden R, Burleson J, Babor T, Apter A, Rounsaville B. Validity of psychiatric diagnoses in patients with substance use disorders: Is the interview more important than the interviewer?. Comprehensive Psychiatry. 1995;36:278–288
  28. Kranzler H, Liebowitz N. Anxiety and depression in substance abuse: Clinical impications. Medical Clinics of North America. 1988;72:867–885
  29. Laqueille X, Poirier M, Jalfre V, Bourdel M, Willard D, Olie J. Predictive factors of response to buprenorphine in the substitutive treatment of heroin addicts. Results of a multicenter study of 73 patients. Presse Medicale. 2001;30:1581–1585
  30. Lee J, Grossman E, DiRocco D, Gourevitch M. Home buprenorphine/naloxone induction in primary care. Journal of General Internal Medicine. 2009;24:226–232
  31. Magura S, Lee S, Salsitz E, Kolodny A, Whitley S, Taubes T, et al. Outcomes of buprenorphine maintenance in office-based practice. Journal of Addictive Diseases. 2007;26:13–23
  32. Maremmani I, Pacini M, Pani P. Effectiveness of buprenorphine in double diagnosed patients: Buprenorphine as a psychotropic drug. Heroin Addiction & Related Clinical Problems. 2006;8:31–48
  33. Mark T, Woody G, Juday T, Kleber H. The economic costs of heroin addiction in the United States. Drug and Alcohol Dependence. 2001;61:195–206
  34. Marlatt G. Taxonomy of high-risk situations for alcohol relapse: Evolution and development of a cognitive–behavioral model. Addiction. 1996;91(Suppl):S37–49
  35. McLellen A, Luborsky L, Woody G, O'Brien C, Druley K. Predicting response to alcohol and drug abuse treatment: Role of psychiatric severity. Archives of General Psychiatry. 1983;40:620–625
  36. Miller I, Bishop S, Norman W, Maddever H. The Modified Hamilton Rating Scale for Depression: Reliability and validity. Psychiatry Research. 1985;14:131–142
  37. Miller W, Westerberg V, Harris R, Tonigan J. What predicts relapse? Prospective testing of antecedent models. Addiction. 1996;91(Suppl):S155–172
  38. Mintzer I, Eisenberg M, Terra M, MacVane C, Himmelstein D, Woolhandler S. Treating opioid addiction with buprenorphine–naloxone in community-based primary care settings. Annals of Family Medicine. 2007;5:146–150
  39. Molenberghs G, Thijs H, Jansen I, Beunckens C, Kenward MG, Mallinckrodt C, et al. Analyzing incomplete longitudinal clinical trial data. Biostatistics. 2004;5:445–464
  40. Nunes E, Goehl L, Seracini A, Deliyannides D, Donovan S, Koenig T, et al. A modification of the structured clinical interview for DSM-III-R to evaluate methadone patients test retest reliability. American Journal on Addictions. 1996;5:241–248
  41. Nunes E, Levin F. Treatment of depression in patients with alcohol or other drug dependence: A meta-analysis. JAMA. 2004;291:1887–1896
  42. Nunes E, Quitkin F, Donovan S, Deliyannides D, Ocepek-Welikson K, Koenig T, et al. Imipramine treatment of opiate dependent patients with depressive disorders: A placebo-controlled trial. Archives of General Psychiatry. 1998;55:153–160
  43. Nunes EV, Sullivan MA, Levin FR. Treatment of depression in patients with opiate dependence. Biol Psychiatry. 2004;56:793–802
  44. O'Connor P, Fiellin D. Pharmacologic treatment of heroin-dependent patients. Annals of Internal Medicine. 2000;133:40–54
  45. Olfson M, Marcus S, Druss B, Ellinson L, Tanielian T, Pincus H. National trends in the outpatient treatment of depression. JAMA. 2002;287:203–209
  46. Papke L, Wooldridge J. Econometric methods for fractional response variables with an application to 401(k) plan participation rates. Journal of Applied Econometrics. 1996;11:619–632
  47. Petrakis I, Carroll K, Nich C, Gordon L, Kosten T, Rounsaville B. Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts. Drug and Alcohol Dependence. 1998;50:221–226
  48. Pirraglia P, Stafford R, Singer D. Trends in prescribing of selective serotonin reuptake inhibitors and other newer antidepressant agents in adult primary care. Primary Care Companion to the Journal of Clinical Psychiatry. 2003;5:153–157
  49. Rounsaville B, Kosten T, Weissman M, Kleber H. Prognostic significance of psychopathology in treated opiate addicts: A 2.5 year follow-up study. Archives of General Psychiatry. 1986;43:739–745
  50. Rounsaville B, Weissman M, Crits-Christoph K, Wilber C, Kleber H. Diagnosis and symptoms of depression in opiate addicts: Course and relationship to treatment outcome. Archives of General Psychiatry. 1982;39:151–156
  51. Simpson D. A conceptual framework for drug treatment process and outcomes. Journal of Substance Abuse Treatment. 2004;27:99–121
  52. Sobell L, Sobell M. Timeline follow-back: A technique for assessing self-reported alcohol consumption. In:  Allen L editors. Measuring Alcohol Consumption. New York: The Humana Press; 1992;p. 41–72
  53. StatCorp . Stata Statistical Software: Release 10. College Station, TX: StatCorp LP; 2007;
  54. Steer R, Iguchi M, Platt J. Use of the revised Beck Depression Inventory with intravenous drug users not in treatment. Psychology of Addictive Behaviors. 1992;6:225–232
  55. Stein M. Medical consequences of substance abuse. The Psychiatric Clinics of North America. 1999;22:351–370
  56. Stein M, Cioe P, Friedmann P. Buprenorphine retention in primary care. Journal of General Internal Medicine. 2005;20:1038–1041
  57. Strain E, Stitzer M, Bigelow G. Early treatment time course of depressive symptoms in opiate addicts. Journal of Nervous and Mental Disease. 1991;179:215–221
  58. Subramaniam G, Lewis L, Stitzer M, Fishman M. Depressive symptoms in adolescents during residential treatment for substance use disorders. American Journal on Addictions. 2004;13:256–267
  59. Tenore PL. Psychotherapeutic benefits of opioid agonist therapy. Journal of Addictive Diseases. 2008;27:49–65
  60. Villafranca SW, McKellar JD, Trafton JA, Humphreys K. Predictors of retention in methadone programs: A signal detection analysis. Drug and Alcohol Dependence. 2006;83:218–224
  61. Wells K, Sherbourne C, Schoenbaum M, Duan N, Meredith L, Unutzer J, et al. Impact of disseminating quality improvement programs for depression in managed primary care: A randomized controlled trial. JAMA. 2000;283:212–220
  62. Woody G, Luborsky L, McLellen A, O'Brien C, Beck A, Blaine J, et al. Psychotherapy for opiate addicts: Does it help?. Archives of General Psychiatry. 1983;40:639–645
  63. Zhang Z, Friedmann P, Gerstein D. Does retention matter? Treatment duration and improvement in drug use. Addiction. 2003;98:673–684

PII: S0740-5472(10)00118-2

doi: 10.1016/j.jsat.2010.05.014

Journal of Substance Abuse Treatment
Volume 39, Issue 2 , Pages 157-166 , September 2010

Article Tools

* Image Usage & Resolution